Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
4 "Jae Young Park"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Application of the International Metastatic Renal Cell Carcinoma Database Consortium and Memorial Sloan Kettering Cancer Center Risk Models in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multi-Institutional Retrospective Study Using the Korean Metastatic Renal Cell Carcinoma Registry
Jung Kwon Kim, Sung Han Kim, Mi Kyung Song, Jungnam Joo, Seong Il Seo, Cheol Kwak, Chang Wook Jeong, Cheryn Song, Eu Chang Hwang, Ill Young Seo, Hakmin Lee, Sung-Hoo Hong, Jae Young Park, Jinsoo Chung, Korean Renal Cell Carcinoma Study Group
Cancer Res Treat. 2019;51(2):758-768.   Published online September 7, 2018
DOI: https://doi.org/10.4143/crt.2018.421
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) and the Memorial Sloan Kettering Cancer Center (MSKCC) risk models were developed predominantly with clear cell renal cell carcinoma (RCC). Accordingly, whether these two models could be applied to metastatic non-clear cell RCC (mNCCRCC) as well has not been well-known and was investigated herein.
Materials and Methods
From the Korean metastatic RCC registry, a total of 156 patients (8.1%) with mNCCRCC among the entire cohort of 1,922 patients were analyzed. Both models were applied to predict first-line progression-free survival (PFS), total PFS, and cancer-specific survival (CSS).
Results
The median first-line PFS, total PFS, and CSS were 5, 6, and 24 months, respectively. The IMDC risk model reliably discriminated three risk groups to predict survival: the median firstline PFS, total PFS, and CSS for the favorable, intermediate, and poor risk groups were 9, 5, and, 2 months (p=0.001); 14, 7, and 2 months (p < 0.001); and 41, 21, and 8 months (p < 0.001), all respectively. The MSKCC risk model also reliably differentiated three risk groups: 9, 5, and, 2 months (p=0.005); 10, 7, and 3 months (p=0.002); and 50, 21, and 8 months (p < 0.001), also all respectively. The concordance indices were 0.632 with the IMDC model and 0.643 with the MSKCC model for first-line PFS: 0.748 and 0.655 for CSS.
Conclusion
The current IMDC and MSKCC risk models reliably predict first-line PFS, total PFS, and CSS in mNCCRCC.

Citations

Citations to this article as recorded by  
  • Advances in non‐clear cell renal cell carcinoma management: From heterogeneous biology to treatment options
    Nathaniel R. Wilson, Yusuf Acikgoz, Elshad Hasanov
    International Journal of Cancer.2024; 154(6): 947.     CrossRef
  • Survival pattern of metastatic renal cell carcinoma patients according to WHO/ISUP grade: a long-term multi-institutional study
    Joongwon Choi, Seokhwan Bang, Jungyo Suh, Chang Il Choi, Wan Song, Hyeong Dong Yuk, Chan Ho Lee, Minyong Kang, Seol Ho Choo, Jung Kwon Kim, Hyung Ho Lee, Jung Ki Jo, Eu Chang Hwang, Chang Wook Jeong, Young Hwii Ko, Jae Young Park, Cheryn Song, Seong Il Se
    Scientific Reports.2024;[Epub]     CrossRef
  • Prognostic Factors and Treatment Outcomes in Renal Cell Carcinoma: A Comprehensive Analysis
    Ömer Faruk ELÇİÇEK, Mehmet KÜÇÜKÖNER
    Namık Kemal Tıp Dergisi.2024; : 217.     CrossRef
  • High Sensitivity Circulating Tumor-DNA Assays in Renal Cell Carcinoma–Are we there yet?
    Fady Sidhom, Shefali Patel, Arpita Desai, Arnab Basu
    Clinical Genitourinary Cancer.2024; 22(6): 102235.     CrossRef
  • Machine learning based prediction for oncologic outcomes of renal cell carcinoma after surgery using Korean Renal Cell Carcinoma (KORCC) database
    Jung Kwon Kim, Sangchul Lee, Sung Kyu Hong, Cheol Kwak, Chang Wook Jeong, Seok Ho Kang, Sung-Hoo Hong, Yong-June Kim, Jinsoo Chung, Eu Chang Hwang, Tae Gyun Kwon, Seok-Soo Byun, Yu Jin Jung, Junghyun Lim, Jiyeon Kim, Hyeju Oh
    Scientific Reports.2023;[Epub]     CrossRef
  • Targeted Literature Review of Outcomes to Initial Systemic Therapy for Advanced/Metastatic Non-Clear Cell Renal Cell Carcinoma in Observational Studies
    Shawna R. Calhoun, Manish Sharma, Chung-Han Lee
    Kidney Cancer.2023; 7(1): 123.     CrossRef
  • A retrospective single-centered, comprehensive targeted genetic sequencing analysis of prognostic survival using tissues from Korean patients with metastatic renal cell carcinoma after targeted therapy
    Sung Han Kim, Jongkeun Park, Weon Seo Park, Dongwan Hong, Jinsoo Chung
    Investigative and Clinical Urology.2022; 63(6): 602.     CrossRef
  • Overall survival in patients with metastatic renal cell carcinoma in Russia, Kazakhstan, and Belarus: a report from the RENSUR3 registry
    Ilya Tsimafeyeu, Oxana Shatkovskaya, Sergei Krasny, Nurzhan Nurgaliev, Ilya Varlamov, Vladislav Petkau, Sufia Safina, Ruslan Zukov, Mikhail Mazhbich, Galina Statsenko, Sergey Varlamov, Olga Novikova, Igor Zaitsev, Pavel Moiseyev, Alexander Rolevich, Alesy
    Cancer Reports.2021;[Epub]     CrossRef
  • The prognostic effect of immunoscore in patients with clear cell renal cell carcinoma: preliminary results
    Ismail Selvi, Umut Demirci, Nazan Bozdogan, Halil Basar
    International Urology and Nephrology.2020; 52(1): 21.     CrossRef
  • Life expectancy in patients with metastatic renal cell carcinoma in the Russian Federation: results of the RENSUR3 multicenter registry study
    I. V. Tsimafeyeu, I. S. Varlamov, V. V. Petkau, S. Z. Safina, R. A. Zukov, M. S. Mazhbich, G. B. Statsenko, S. A. Varlamov, I. V. Zaitsev, O. Yu. Novikova, S. А. Krasny, N. S. Nurgaliyev, I. L. Popova, L. Yu. Vladimirova
    Malignant tumours.2019; 9(2): 45.     CrossRef
  • 10,578 View
  • 243 Download
  • 12 Web of Science
  • 10 Crossref
Close layer
Correlation of Androgen Deprivation Therapy with Cognitive Dysfunction in Patients with Prostate Cancer: A Nationwide Population-Based Study Using the National Health Insurance Service Database
Bum Sik Tae, Byung Jo Jeon, Seung Hun Shin, Hoon Choi, Jae Hyun Bae, Jae Young Park
Cancer Res Treat. 2019;51(2):593-602.   Published online July 18, 2018
DOI: https://doi.org/10.4143/crt.2018.119
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study was to evaluate the association of androgen deprivation therapy (ADT) with cognitive dysfunction.
Materials and Methods
Using the National Health Insurance Service database of the entire Korean adult prostate cancer population (n=236,391), data on ADT and cognitive dysfunction between 2008 and 2015 were analyzed. We excluded patients previously diagnosed with cognitive dysfunction, dementia, or a cerebral event history. We tested the effect of ADT on the risk of cognitive dysfunction using propensity score–matched Cox proportional hazards regression models and Kaplan-Meier survival analysis. Our final cohort comprised of 35,401 individuals with prostate cancer, including 24,567 men (70.6%) who underwent ADT.
Results
During a mean follow-up period of 4.1 years, 4,741 patients were newly diagnosed with cognitive dysfunction. A statistically significant association was found between ADT and the risk of cognitive dysfunction (hazard ratio, 1.169; p=0.002). Meanwhile, age (≥ 70 years), diabetes, hypertension, cardiovascular history, and peripheral vascular disease were identified as factors that contribute to the increased risk of cognitive dysfunction. In contrast, the use of statins and aspirin was associated with a lower risk of cognitive dysfunction. Kaplan-Meier analysis demonstrated that patients aged 70 years or older who underwent ADT had the lowest cumulative probability of remaining cognitive dysfunction-free (log-rank p < 0.001).
Conclusion
Our results revealed an association between the use of ADT for the treatment of prostate cancer and an increased risk of cognitive dysfunction in a nationwide population-based study. This finding should be further evaluated in prospective studies.

Citations

Citations to this article as recorded by  
  • Unraveling the bidirectional link between cancer and dementia and the impact of cancer therapies on dementia risk: A systematic review and meta‐analysis
    Liwei Ma, Edwin C. K. Tan, Benjamin Goudey, Liang Jin, Yijun Pan
    Alzheimer's & Dementia.2025;[Epub]     CrossRef
  • Androgen deprivation therapy for prostate cancer and neurocognitive disorders: a systematic review and meta-analysis
    David E. Hinojosa-Gonzalez, Affan Zafar, Gal Saffati, Shane Kronstedt, Dimitar V. Zlatev, Mohit Khera
    Prostate Cancer and Prostatic Diseases.2024; 27(3): 507.     CrossRef
  • Antineoplastics for treating Alzheimer's disease and dementia: Evidence from preclinical and observational studies
    Viswanath Das, John H. Miller, Charanraj Goud Alladi, Narendran Annadurai, Juan Bautista De Sanctis, Lenka Hrubá, Marián Hajdúch
    Medicinal Research Reviews.2024; 44(5): 2078.     CrossRef
  • Cognitive effects of long‐term androgen deprivation therapy in older men with prostate cancer
    Denise Pergolizzi, Kathleen R. Flaherty, Rebecca M. Saracino, James C. Root, Elizabeth Schofield, Caroline Cassidy, Vani Katheria, Sunita K. Patel, William Dale, Christian J. Nelson
    Psycho-Oncology.2024;[Epub]     CrossRef
  • Psychosocial Factors Associated with Cognitive Function in Prostate Cancer Survivors on Hormonal Treatments: A Systematic Review
    Lorna Pembroke, Kerry A. Sherman, Heather Francis, Haryana M. Dhillon, Howard Gurney, David Gillatt
    Neuropsychology Review.2024;[Epub]     CrossRef
  • Androgen deprivation therapy exacerbates Alzheimer’s-associated cognitive decline via increased brain immune cell infiltration
    Chao Zhang, Mae Aida, Shalini Saggu, Haiyan Yu, Lianna Zhou, Hasibur Rehman, Kai Jiao, Runhua Liu, Lizhong Wang, Qin Wang
    Science Advances.2024;[Epub]     CrossRef
  • Risks associated with cognitive function and management strategies in the clinical use of ADT: a systematic review from clinical and preclinical studies
    Meng-fan Cui, Li-ming Chen, Cindy Jiang, Bing-zhe Ma, Fu-wen Yuan, Chen Zhao, Shi-min Liu
    Supportive Care in Cancer.2024;[Epub]     CrossRef
  • Urogeriatrisches Denken am Beispiel der antiandrogenen Therapie des Prostatakarzinoms
    A. Wiedemann, A. Manseck, J. Stein, M. Fröhner, C. Fiebig, A. Piotrowski, R. Kirschner-Hermanns
    Die Urologie.2024; 63(9): 867.     CrossRef
  • Untangling the role of tau in sex hormone responsive cancers: lessons learnt from Alzheimer's disease
    Rachel M. Barker, Alfie Chambers, Patrick G. Kehoe, Edward Rowe, Claire M. Perks
    Clinical Science.2024; 138(21): 1357.     CrossRef
  • A Systematic Review on the Potential Acceleration of Neurocognitive Aging in Older Cancer Survivors
    Charlotte Kerstens, Hans P. M. W. Wildiers, Gwen Schroyen, Mercedes Almela, Ruth E. Mark, Maarten Lambrecht, Sabine Deprez, Charlotte Sleurs
    Cancers.2023; 15(4): 1215.     CrossRef
  • Comparison of Cerebral Blood Flow in Regions Relevant to Cognition After Enzalutamide, Darolutamide, and Placebo in Healthy Volunteers: A Randomized Crossover Trial
    Steven C. R. Williams, Ndaba Mazibuko, Owen O’Daly, Christian Zurth, Fiona Patrick, Christian Kappeler, Iris Kuss, Patricia E. Cole
    Targeted Oncology.2023; 18(3): 403.     CrossRef
  • Does ADT Influence the Risk of Suicidal Ideation among US Veteran Prostate Cancer Patients Pre-Exposed to PTSD?
    Smit Brahmbhatt, Herta H. Chao, Shiv Verma, Sanjay Gupta
    Cancers.2023; 15(10): 2739.     CrossRef
  • Androgen deprivation therapy and risk of cognitive dysfunction in men with prostate cancer: is there a possible link?
    Myungsun Shim, Woo Jin Bang, Cheol Young Oh, Yong Seong Lee, Jin Seon Cho
    Prostate International.2022; 10(1): 68.     CrossRef
  • Impact of Testosterone on Alzheimer’s Disease
    Vittorio Emanuele Bianchi
    The World Journal of Men's Health.2022; 40(2): 243.     CrossRef
  • Androgen‐targeting therapeutics mitigate the adverse effect of GnRH agonist on the risk of neurodegenerative disease in men treated for prostate cancer
    Gregory L. Branigan, Georgina Torrandell‐Haro, Maira Soto, Edward P. Gelmann, Francesca Vitali, Kathleen E. Rodgers, Roberta Diaz Brinton
    Cancer Medicine.2022; 11(13): 2687.     CrossRef
  • Assessment and Management of Cognitive Function in Patients with Prostate Cancer Treated with Second-Generation Androgen Receptor Pathway Inhibitors
    Jeffrey S. Wefel, Charles J. Ryan, Julie Van, James C. Jackson, Alicia K. Morgans
    CNS Drugs.2022; 36(5): 419.     CrossRef
  • The Insignificant Correlation between Androgen Deprivation Therapy and Incidence of Dementia Using an Extension Survival Cox Hazard Model and Propensity-Score Matching Analysis in a Retrospective, Population-Based Prostate Cancer Registry
    Young Ae Kim, Su-Hyun Kim, Jae Young Joung, Min Soo Yang, Joung Hwan Back, Sung Han Kim
    Cancers.2022; 14(11): 2705.     CrossRef
  • Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
    David Conde-Estévez, Iván Henríquez, Jesús Muñoz-Rodríguez, Alejo Rodriguez-Vida
    Expert Opinion on Drug Metabolism & Toxicology.2022; 18(9): 601.     CrossRef
  • Testosterone and Alzheimer’s disease
    K. O. Kuznetsov, R. R. Khaidarova, R. H. Khabibullina, E. S. Stytsenko, V. I. Filosofova, I. R. Nuriakhmetova, E. M. Hisameeva, G. S. Vazhorov, F. R. Khaibullin, E. A. Ivanova, K. V. Gorbatova
    Problems of Endocrinology.2022; 68(5): 97.     CrossRef
  • Quantifying observational evidence for risk of dementia following androgen deprivation therapy for prostate cancer: an updated systematic review and meta-analysis
    Haiying Cui, Yao Wang, Fei Li, Guangyu He, Zongmiao Jiang, Xiaokun Gang, Guixia Wang
    Prostate Cancer and Prostatic Diseases.2021; 24(1): 15.     CrossRef
  • Risk of Cognitive Effects in Comorbid Patients With Prostate Cancer Treated With Androgen Receptor Inhibitors
    Alicia K. Morgans, Joseph Renzulli, Kara Olivier, Neal D. Shore
    Clinical Genitourinary Cancer.2021; 19(5): 467.e1.     CrossRef
  • Association between Androgen Deprivation Therapy and Risk of Dementia in Men with Prostate Cancer
    Jui-Ming Liu, Chin-Yao Shen, Wallis C. Y. Lau, Shih-Chieh Shao, Kenneth K. C. Man, Ren-Jun Hsu, Chun-Te Wu, Edward Chia-Cheng Lai
    Cancers.2021; 13(15): 3861.     CrossRef
  • Prostate cancer treatment and the relationship of androgen deprivation therapy to cognitive function
    A. B. Reiss, U. Saeedullah, D. J. Grossfeld, A. D. Glass, A. Pinkhasov, A. E. Katz
    Clinical and Translational Oncology.2021; 24(5): 733.     CrossRef
  • Biomarkers to Evaluate Androgen Deprivation Therapy for Prostate Cancer and Risk of Alzheimer’s Disease and Neurodegeneration: Old Drugs, New Concerns
    Vérane Achard, Kelly Ceyzériat, Benjamin B. Tournier, Giovanni B. Frisoni, Valentina Garibotto, Thomas Zilli
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Does androgen deprivation impact associations between cognition and strength, fitness and function in community-dwelling men with prostate cancer? A cross-sectional study
    Niamh L Mundell, Patrick J Owen, Jack Dalla Via, Helen Macpherson, Robin M Daly, Steve F Fraser
    BMJ Open.2021; 11(12): e058478.     CrossRef
  • Antiaging Therapies, Cognitive Impairment, and Dementia
    Devin Wahl, Rozalyn M Anderson, David G Le Couteur, Rafael de Cabo
    The Journals of Gerontology: Series A.2020; 75(9): 1643.     CrossRef
  • A review of prostate cancer treatment impact on the CNS and cognitive function
    Charles Ryan, Jeffrey S. Wefel, Alicia K. Morgans
    Prostate Cancer and Prostatic Diseases.2020; 23(2): 207.     CrossRef
  • Diagnostic accuracy of administrative database for bile duct cancer by ICD-10 code in a tertiary institute in Korea
    Young-Jae Hwang, Seon Mee Park, Soomin Ahn, Jongchan Lee, Young Soo Park, Nayoung Kim
    Hepatobiliary & Pancreatic Diseases International.2020; 19(6): 575.     CrossRef
  • WITHDRAWN: The Changes of ADC Value, DCE-MRI Parameters and Their Influence on Neuropsychology in Prostate Cancer Patients after Endocrine Therapy Based on Magnetic Resonance Imaging
    Yang Lu, Shang Ge, Yan Liu, Gengji Bai
    Neuroscience Letters.2020; : 135221.     CrossRef
  • Neuropsychiatric Impact of Androgen Deprivation Therapy in Patients with Prostate Cancer: Current Evidence and Recommendations for the Clinician
    Aisha L. Siebert, Leiszle Lapping-Carr, Alicia K. Morgans
    European Urology Focus.2020; 6(6): 1170.     CrossRef
  • An Updated Review: Androgens and Cognitive Impairment in Older Men
    Zhonglin Cai, Hongjun Li
    Frontiers in Endocrinology.2020;[Epub]     CrossRef
  • Risk of dementia and Parkinson’s disease in patients treated with androgen deprivation therapy using gonadotropin-releasing hormone agonist for prostate cancer: A nationwide population-based cohort study
    Myungsun Shim, Woo Jin Bang, Cheol Young Oh, Yong Seong Lee, Seong Soo Jeon, Hanjong Ahn, Young-Su Ju, Jin Seon Cho, Gianluigi Forloni
    PLOS ONE.2020; 15(12): e0244660.     CrossRef
  • Androgen deprivation therapy for prostate cancer and risk of dementia
    David Robinson, Hans Garmo, Mieke Van Hemelrijck, Jan‐Erik Damber, Ola Bratt, Lars Holmberg, Lars‐Olof Wahlund, Pär Stattin, Jan Adolfsson
    BJU International.2019; 124(1): 87.     CrossRef
  • Investigational luteinizing hormone releasing hormone (LHRH) agonists and other hormonal agents in early stage clinical trials for prostate cancer
    Nirmish Singla, Rashed A. Ghandour, Ganesh V. Raj
    Expert Opinion on Investigational Drugs.2019; 28(3): 249.     CrossRef
  • Cognitive functioning in thyroid cancer survivors: a systematic review and meta-analysis
    Omar Saeed, Lori J. Bernstein, Rouhi Fazelzad, Mary Samuels, Lynn A. Burmeister, Lehana Thabane, Shereen Ezzat, David P. Goldstein, Jennifer Jones, Anna M. Sawka
    Journal of Cancer Survivorship.2019; 13(2): 231.     CrossRef
  • Is androgen deprivation therapy associated with cerebral infarction in patients with prostate cancer? A Korean nationwide population‐based propensity score matching study
    Bum Sik Tae, Byeong Jo Jeon, Hoon Choi, Jae Hyun Bae, Jae Young Park
    Cancer Medicine.2019; 8(9): 4475.     CrossRef
  • 9,428 View
  • 293 Download
  • 37 Web of Science
  • 36 Crossref
Close layer
Changing Trends of Clinical Aspects in Lung Cancer from 1988 to 1996 - Hostipal Based Study
Jung Suk Kim, Jae Young Park, Sang Chul Chae, Moo Chul Shin, Moon Seob Bae, Ji Woong Son, Kwan Young Kim, Tae Kyung Kang, Ki Soo Park, Chang Ho Kim, Sin Kam, Tae Hoon Jung
J Korean Cancer Assoc. 1999;31(1):112-119.
AbstractAbstract PDF
PURPOSE
Lung cancer is now one of the most frequently diagnosed cancers in the world and its incidence has been increasing also in Korea. In several recent studies, the indidence of adenocarcinoma and female/male ratio have been reported to be increasing. The aim of this study is to investigate the changing trends in sex and age distribution, the histologic type and location (peripheral or central) of tumors in lung cancer.
MATERIALS AND METHODS
We performed the retrospective review of histopathology and clinical information of 1409 patients diagnosed as baving primary lung cancer, except non-epithelial tumors and undetermined histologic types, at Kyungpook National University Hospital from January 1988 to December 1996.
RESULTS
Male to female ratio was 4.6; 1. The peak incidence of age group was 7th decade (40.3%) with mean age of 61.5. Percentage of smokers in patients with lung cancer was 84.3%. Total number of patients with lung cancer has increased recently. However, the annual female/male ratio was nearly constant during the study period. Peripheral tumors, which were found in 20.6% of patients with lung cancer in 1988, increased to 33.5% in 1996 and this trend was more prominent in squamous cell carcinoma than in adenocarcinoma. Squamous cell carcinoma was the most common histologic type (62.0%), followed by adenocarcinoma (19.2%), small cell carcinoma (14.2%), large cell carcinoma (4.6%) in order. There was a predominance of squamous cell carcinoma (67.9%) in males and of adenocarcinoma (46.6%) in females. There has been a significant shift in the histology pattern with an increase in the percentage of adenocarcinoma. The incidence of adenocarcinoma was more than doubled from 7.5% in 1988 to 25.8% in 1996.
CONCLUSION
These findings suggest that the epidemiology of lung cancer is changing.
  • 2,969 View
  • 15 Download
Close layer
Inquiry about Management of Non-Small Cell Lung Cancer
Jae Young Park, Jung Suk Kim, Sin Kam, Sang Chul Chae, Jun Hee Won, Chang Ho Kim, Jae Chul Kim, Sang Hoon Jun, In Kyu Park, Tae Hoon Jung
J Korean Cancer Assoc. 1998;30(2):214-224.
AbstractAbstract PDF
PURPOSE
In recent years there has been a considerable increase in the use of chemotherapy as an adjuvant to surgery, radical radiotherapy and in addition to best supportive care. However, the value of chemotherapy in improving survival is still unclear, despite more than 50 randomised trials addressing this question in the different stages of disease. This study was done to evaluate Korean doctors' personal management preference and their beliefs about prognosis in non-small celllung cancer(NSCLC).
MATERIALS AND METHODS
A mail survey of Korean respirologists, thoracic surgeons, radiation oncologists, and medical oncologists was performed. Four cases of NSCLC were described and respondents were asked to give their treatment recommendations and to estimate the prognosis in each case.
RESULTS
After a complete resection for stage II NSCLC, 27% recommended no adjuvant treatment, 36% recommended radiotherapy, 18% recommended chemotherapy, and 19% recommended both radiotherapy and chemotherapy. After a complete resection for stage IIIA(N2) NSCLC, the vast majority of respondents recommended adjuvant therapy. For an asymptomatic patient with stage IIIB NSCLC, 5% recommended supportive care, 24% recommended radiotherapy, 16% recommended chemotherapy, and 54% recommended chemotherapy combined with radiotherapy. For a patient with stage IV NSCLC, 76% recommended chemotherapy with or without palliative radiotherapy. Doctors' treatment preference was significantly different by their speciliaty in a case with stage II, IIIA(N2), or IV NSCLC. Most respondents believed that chemotherapy would increase survival in NSCLC. Doctors' beliefs about the efficacy of treatment were strongly associated with their treatment recommendations.
CONCLUSION
Korean doctors generally preferred relatively aggressive management although their personal preferences varied widely. Team approach is important in deciding the treatment modality because doctors' treatment preference is different by their speciality.
  • 3,441 View
  • 14 Download
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP